Full Length Research Paper

# Efficacy and safety profile of moxifloxacin in treatment of urogenital system infections: A meta-analysis of randomized controlled trials

Yanping Mu<sup>1</sup>, Jinyu Huang<sup>2</sup>, Ruilin Liu<sup>3</sup>, Xun Deng<sup>1</sup>, Liqing Wang<sup>1</sup>, Ping Fang<sup>4</sup>, Meidan Wei<sup>1</sup>, and Yong Wang<sup>1</sup>\*

<sup>1</sup>Department of Clinical Pharmacology, Zhujiang Hospital, Southern Medical University, Guangzhou 520282, China.
<sup>2</sup>Department of Stomatology, Zhujiang Hospital, Southern Medical University, Guangzhou 520282, China.
<sup>3</sup>hujiang Hospital, Southern Medical University, Guangzhou 520282, China.
<sup>4</sup>Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 520282, China.

Accepted 26 March, 2012

This meta-analysis was performed to evaluate the efficacy and safety profile of moxifloxacin in treatment of urogenital system infections. PubMed, EMBASE, Science Direct, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, CBM (Chinese Biomedical Literature Database), CNKI (Chinese National Knowledge Infrastructure), Wan Fang Data and VIP INFORMATION were searched from January 1999 to May 2011 to comprehensively collect randomized controlled trials (RCTs) that compared moxifloxacin with conventional antibiotics therapy in patients with urogenital system infections. Clinical cure rates, clinical effective rates, pathogens eradication rates and incidence of adverse drug reactions were pooled using meta-analysis performed by Review Manager 5.1 software. Relative risk (RR) and 95% confidence interval (95%CI) were calculated in a random-effects model or in a fixed-effects model. Twenty-two trials including a total of 3940 patients were included for meta-analysis. The results of meta analysis showed that clinical cure rates, clinical effective rates and pathogens eradication rates of moxifloxacin were higher than conventional therapy [RR = 1.08, 95%CI (1.02, 1.14), P = 0.008; RR = 1.09, 95%CI (1.04, 1.14), P = 0.0005; RR = 1.04, 95%Cl (0.99, 1.09), P = 0.08]; the incidences of adverse drug reactions between moxifloxacin and control group were not statistically significant [RR = 0.88, 95%CI (0.72, 1.06), P = 0.17]. In three large studies of pelvic inflammatory disease (PID) patients, no statistically significant difference was found between moxifloxacin monotherapy group and control group about clinical cure rates, microbiological success rates and the incidences of adverse drug reactions [RR = 0.98, 95%CI (0.95, 1.02), P = 0.33; RR = 1.06, 95%CI (0.96, 1.16), P = 0.25; RR = 0.85, 95%CI (0.68, 1.05), P = 0.13]. Moxifloxacin can be suggested as the regimen of choice for treatment of urogenital system infections.

Key words: Meta-analysis, moxifloxacin, efficacy, urogenital system infections, pelvic inflammatory disease.

# INTRODUCTION

Urogenital system infections are among the most frequently seen and encountered infectious diseases of humans in the world. They are one of the leading causes of acute diseases and chronic health impairment (Skerk et al., 2010; Hannan et al., 1993). Urinary tract infections mainly include pyelonephritis, cystitis, urethritis, while

genital system infections cover pelvic inflammation disease (PID), vaginitis, and cervicitis in women and prostatitis in men. Anatomically, the urinary and genital systems are close, and susceptible to cross-infection. Sexually transmitted infections are important public health problem, numerous complications leaving permanent consequences on the human health as well as large expenses that health-care system and individuals have to pay for their detection, prevention and treatment (Skerk et al., 2010; Minichiello et al., 2011). Urinary tract infections

<sup>\*</sup>Corresponding author: E-mail: ywang43555@sina.com.

are the most common bacterial infections in humans and the most common reason for justified antibiotic prescriptions (Foxman ., 2002).

Urogenital system infections are mostly caused by Escherichia coli, Enterococcus, Staphylococcus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Proteus mirabilis (Bebear et al., 2008). For the past few years, some atypical pathogens, such as Mycoplasma and Chlamydia, are accounting for more and more infections (Wagenlehner Naber. 2006). and Fluoroguinolones which are among the alternatives for empirical antibiotic treatment of some urogenital system infections have become widely accepted for treatment of urogenital system infections because of their favorable pharmacokinetic and pharmacodynamic properties . (Pathania and Sharma., 2010; Wagenlehner and Naber., 2006; Naber, 2001). Clinical practice has proved that fluoroquinolones are a good choice for urogenital system infections (Wagenlehner and Naber, 2006). However, the most important drawback in the treatment of urogenital system infections is that bacterial resistance quickly appears. A four-year prospective study reported that there is high intrinsic resistance to the quinolones among strains of Pseudomonas aeruginosa (43.4%), E. coli (26.3%) and Proteus spp. (17.1%), and rising rates of resistance were observed in P. aeruginosa (14.6% increase), Staphylococcus aureus (9.8%), and E. coli (9.7%) after four years (Omigie et al., 2009).

Moxifloxacin, a new fluoroquinolone antibiotic that acts by inhibiting bacterial topoisomerases II and IV, not only possesses increased activity against typical, atypical and anaerobic bacteria, but also has enhanced potential to minimize the emergence of bacterial resistance (Bebear et al., 2008; Lode and Schmidt., 2008a; Boswell et al., 2002; Brueggemann et al., 1997). There is no known cross-resistance between moxifloxacin and other kinds of antimicrobials, such as beta-lactams, macrolides, aminoglycosides and tetracyclines (Keating and Scott, 2004). Moxifloxacin achieves good tissue penetration and high concentrations in clinically relevant tissues and fluids (Lode and Schmidt, 2008b). Based on the safety profile and the pharmacokinetic behavior of moxifloxacin, a dosage regimen of 400 mg given once daily, are effective and well tolerated for the treatment of various infections (Stass et al., 2001). Moxifloxacin, taken as respiratory fluoroquinolone, is mainly used for the treatment of acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia (Miravitlles, 2005), acute bacterial sinusitis (Lode et al., 2008b), complicated skin and skin-structure infections (Muijsers and Jarvis, 2010) and complicated intra-abdominal infections (Cheadle et al., 2010). Because of the desirable pharmacokinetic and concentration in tissues and fluids, we want to find out whether moxifloxacin can be considered as an alternative for the treatment of urogenital infections. Although Naber et al. (Bebear et al., 2008) discovered that the urinary excretion of moxifloxacin (20%) was lower than

ciprofloxacin (43%), ofloxacin (81%) and levofloxacin (84%) and the indications of moxifloxacin are not included urogential infections (Foxman et al., 2011), in some countries, such as China, France, Russia, and England, moxifloxacin is used for treatment of urogenital system infections (Zheng, 2010; Su et al., 2010; Judin et al., 2010; Meng and Ding, 2009; Tang et al., 2009; Wang and Pei, 2009a, b; Jin et al., 2009; Wang et al., 2009; Zhang et al., 2009; Heystek and Ross, 2009; Li, 2008; Per et al., 2009; Zhang et al., 2006; Luo et al., 2006; Gao et al., 2005; Tian et al., 2005; Zhang et al., 2004; Cai et al., 2003).

Research findings from those clinical studies of the efficacy and safety profile of moxifloxacin in treatment of urogenital system infections have been inconsistent. Therefore, aiming to compare the efficacy and safety profile of moxifloxacin monotherapy with conventional antibiotic treatment for treatment of urogenital infections, we conduct a meta-analysis of randomized controlled trials (RCTs).

## MATERIALS AND METHODS

### Data sources

Studies were identified by extensively searching the PubMed, EMBASE, Science Direct, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials, CBM (Chinese Biomedical Literature Database), CNKI (Chinese National Knowledge Infrastructure), Wan Fang Data and VIP INFORMATION were searched from January 1999 to May 2011. The search terms were moxifloxacin, Avelox, urinary tract infections, urogenital infections, pelvic inflammatory disease and nongonococcal urethritis. The language of the literatures was not restricted to English. In addition, references of the relevant articles were reviewed in order to identify additional studies not detected by the initial search.

### Study selection

Two reviewers (Yanping Mu and Xun Deng) independently searched literatures and examined relevant randomized controlled trials (RCTs). Any disagreement about study selection or data extraction was resolved by consensus with the third reviewer (Yong Wang, MD). For meta-analysis, all studies had to meet the following inclusion criteria: (1) A study described as RCT; (2) patients with urogenital infections had no statistically significant differences in baseline characteristics; (3) comparison of the efficacy and safety of moxifloxacin and other conventional antibiotics; (4) The outcome measures were clinical treatment success (defined as "clinical cure" and "clinical effective". "Clinical cure" was the normalization of acute signs, symptoms related to infection and laboratory test results with no requirement for further antibiotic therapy, and "clinical effective" was the aggregation of cure and improvement), microbiological treatment success (defined as the eradication of baseline pathogens) and adverse drug reactions.

Non-randomized studies were excluded, as well as case reports, reviews with insufficient details to meet the inclusion criteria, abstracts in the proceedings of scientific conferences, experimental trials and trials focusing on pharmacokinetics or pharmacodynamics, and children and pregnant female.

### **Data extraction**

Two of the authors independently extracted data from the trials that



Figure 1. Flow diagram of the process for selecting articles for a meta-analysis of moxifloxacin compared with conventional medical treatment in the treatment of urogenital infections.

met the inclusion criteria using. Authors would be contacted for missing data when necessary. For each trial, the following data were extracted: disease; number of patients in each group; mean age and sex distribution of each group; drug regimen, including doses and treatment duration; clinical cure rates; clinical effective rates; pathogens eradication rates and the incidences of adverse drug reaction.

#### Assessment of study quality

Quality assessment of the RCTs included in the meta-analysis was independently performed by the same reviewers according to Cochrane Handbook 5.0.1 and Juni et al. (Juni et al., 2001; Jadad et al., 1996), which assesses the descriptions of randomization procedures, allocation concealment, double blinding and dropouts\withdrawals of the included trials. Each author rated the quality of the trials using Jadad grade (maximum grade=A; minimum grade = C; grade  $\ge B = \text{good quality}$ ).

#### Statistical analysis

Data were analyzed using Review Manager 5.1. Included articles were pooled and weighed (Juni et al., 2009). Relative risk (RR) and 95% confidence interval (95%CI) were calculated in a random-effects model or in a fixed-effects model. Heterogeneity was assessed by calculating a  $\chi^2$  test and the quantity of heterogeneity was measured with  $\hat{P}$  statistic. If heterogeneity (P<0.1 or  $\hat{P}$ >50%) was found among the trials, random-effects model would be chosen, otherwise fixed-effects model chosen. If heterogeneity was evident ( $\hat{P}$ >70%), the inferior quality study should be eliminated to analyze.

## RESULTS

### Study selection process

The flow diagram (Figure 1) shows the process of selecting articles for meta-analysis of moxifloxacin compared with conventional therapy for urogenital infections. Twenty-two (Zheng, 2010; Su et al., 2010; Judin et al., 2010; Meng et al., 2009; Tang et al., 2009; Wang and Pei, 2009a; Wang and Pei, 2009b; Jin et al., 2009; Wang et al., 2009; Zhang et al., 2009; Heystek and Ross, 2009; Li, 2008; Per et al., 2009; Zhang et al., 2006; Luo et al., 2007; Sun, 2007; Ross et al., 2006; Luo et al., 2006; Luo et al., 2006; Gao et al., 2005; Tian et al., 2005; Zhang et al., 2004; Cai et al., 2003) were finally selected from the 112 articles.

## Study characteristics

The main characteristics of twenty-two included RCTs are presented in Table 1. Twenty-two RCTs involving 3940 patients were ultimately confirmed that met the criteria for inclusion in the meta-analysis. Among the patients included in the trials, the mean age was 36.87 years, and 82.61% (3255/3940) of the patients were women. All of the trials enrolled patients with urogential system infections, nine of which were researched patients with

Study	Country	Type of disease	Treatment	No. of patients (male/female)	Mean age, y	Drug regimen	Clinical cure rate	Clinical effective rate	Pathogen eradication rate	Incidence of ADR
			MFX	32 (20/12)	40.8 ± 4.1	400 mg, po, qd × 10d	75.0 (24/32)	90.6 (29/32)	87.5	9.4 (3/32)
HZ 2010	China	UII	LVFX	31 (19/12)	39.8 ± 3.7	200 mg, po, bid × 10d	64.5 (20/31)	87.1 (27/31)	74.2	6.6 (2/31)
Su XD <sup>24</sup>	China	NGU	MFX	60 (60/0)	32	400 mg, po, qd × 14d	40.0 (24/60)	90.0 (54/60)	-	6.7 (4/60)
2010	Onina	NGO	AZI	60 (60/0)	34	500 mg, po,qd × 14d	33.3 (20/60)	71.7 (43/60)	-	10.0 (6/60)
Judlin <sup>25</sup>	Franco	חוס	MFX	228 (0/228)	35.2 ± 8.4	400 mg, po, qd × 14d	78.4 (152/194)	-	90.0 (27/30)	56.6 (129/228)
2010	FIGUCE	FID	LVFX/MTZ	232 (0/232)	35.4 ± 8.7	500 mg LVFX,po,qd + 500 mg MTZ, po, bid × 14d	81.6 (155/190)	-	84.6 (22/26)	56.9 (132/232)
Meng W <sup>26</sup>	China		MFX	25 (0/25)		400 mg po, qd ×14d	92.0 (23/25)	100.0 (25/25)	-	16.0 (4/25)
2009	China	Acute PID	CTRX/AZI	25 (0/25)	19~61	CTRX250 mg, im, qd + AZI500 mg,po,qd ×14d	80.0 (20/25)	96.0 (24/25)	-	32.0 (8/25)
Tang JD <sup>27</sup>	China		MFX	50 (8/42)		400 mg, iv, qd × 3d or 14d	86.0 (43/50)	92.0 (46/50)	91.5 (43/47)	6.0 (3/50)
2009	China	UTI	OFLX	50 (7/43)	43.1 ± 25.6	200 mg, iv, bid × 3d or 14d	84.0 (42/50)	90.0 (45/50)	91.3 (42/46)	6.0 (3/50)
			MFX	80 (0/80)	18 ~ 58	400 mg, po, qd ×14d	56.3 (45/80)	91.3 (73/80)	90.0 (72/80)	10.0 (8/80)
Wang G <sup>28</sup> 2009(a)	China	NGU	AZI	80 (0/80)		500 mg, po, qd × 14d	55.0 (44/80)	91.3 (73/80)	91.3 (73/80)	6.3 (5/80)
			MINO	80 (0/80)		100 mg, po, bid × 14d	57.5 (46/80)	93.8 (75/80)	92.5 (74/80)	11.3 (9/80)
Wang G <sup>29</sup>	China		MFX	150 (0/150)		400 mg, po, qd × 7d	60.0 (90/150)	96.0 (144/150)	89.9 (169/188)	8.0 (12/150)
2009(b)	Unina	011	GAT	149 (0/149)	31 ± 0.5	400 mg, po, qd × 7 d	56.4 (84/149)	95.3 (142/149)	87.1 (162/186)	8.7 (13/149)

# Table 1. Study characteristics of included RCTs.

Table 1 cont

				101		100 mg, ng gd 10d	93.4	95.1	95.7	0.4.(44/404)
Jin X <sup>30</sup>	China	UTI	IVIF X	121	-	400 mg, po,qa × 10a	(113/121)	(115/121)	(116/121)	9.1 (11/121)
2009		-	SPFX	121		300 mg ,po,qd × 10d	92.6 (112/121)	95.9 (116/121)	96.7 (117/121)	9.1 (11/121)
Wang X <sup>31</sup>	China	NGU	MFX	60 (0/60)	-	400 mg, po, qd × 12d	63.3 (38/60)	81.7 (49/60)	-	5.0 (3/60)
2009	Grina	NGU	CLA	60 (0/60)		500 mg, po, qd × 12d	48.3 (29/60)	65.0 (39/60)	-	0 (0/60)
Zhang YH <sup>32</sup>	China	UTI	MFX	40 (23/17)	39 ± 8	400 mg, iv, qd × 7d	87.5 (35/40)	95.0 (38/40)	77.5 (31/40)	5.0 (2/40)
2009	China	011	GAT	40 (24/16)	37 ± 9	400 mg, iv, qd × 7d	85.0 (34/40)	92.5 (37/40)	76.9(30/39)	7.5 (3/40)
Hovetok <sup>33</sup>			MFX	232 (0/232)	29.1 ± 7.2	400mg,po, qd ×14d	96.5 (224/232)	-	93.5 (43/46)	44.0 (151/343)
2009	England	PID	DOX/MTZ/CPFX	202 (0/202)	28.5 ± 7.0	DOX 100 mg, bid × 14d + MTZ400 mg, tid × 14d + CPFX500 mg	98.0 (198/202)	-	89.7 (35/39)	49.7 (162/326)
Li SQ <sup>34</sup>	China		MFX	90		400 mg, po, qd × 10d	94.4 (85/90)	97.8 (88/90)	96.7 (87/90)	7.8 (7/90)
2008	China	011	LVFX	86		200mg,po,bid × 10d	86.0 (74/86)	91.9 (79/86)	94.2 (81/86)	9.3 (8/86)
Pei YH <sup>35</sup>	Ohina		MFX	62 (0/62)	30.5	400mg,po,qd ×14d	66.1 (41/62)	91.9 (57/62)	89.5 (51/57)	8.1 (5/62)
2008	China	Female RTI	CPFX	50 (0/50)		200 mg, po, bid × 14d	40.0 (20/50)	62.0 (31/50)	72.7 (32/44)	-
Zhang	China	Urogential	MFX	38 (26/12)	45 ± 13	400 mg, po, qd × 7d	60.5 (23/38)	86.8 (33/38)	91.3 (42/46)	2.6 (1/38)
2007	Unina	infections	GAT	38 (25/13)	45 ± 12	200 mg, ivgtt, bid × 7d	63.2 (24/38)	89.5 (34/38)	92.0 (46/50)	5.3 (2/38)

Table 1. contd.

Sun GQ <sup>37</sup> Orof         China         NGU         MFX AZI         45 (26/19) (1 (26/15)         28.3 ± 11 (27.36 ± 12)         400 mg, po, qd x 12 - 14d         75.0 (31/41)         91.8 (45/49)         18.2 (8/4)           Ross <sup>38</sup> 2006         England         PlD         MFX 2         384 (0/384)         30.1 ± 8.4         400 mg, po, qd x 12 - 14d         90.2 (240/27)         -         87.5 (43/85)         22.5 (85/378)           2006         PlD         MFX         365 (0/366)         30.5 ± 8.5         400 mg, po, qd x 12-d14d         90.2 (240/27)         -         87.5 (43/85)         22.5 (85/378)           2006         China         UTI and RTI         MFX         56 (0/56)         27.6 ± 3.1         400mg, po, qd x 12d         78.6 (44/56)         91.1 (51/56)         -         73.2 (41/56)           2006         China         Urogential         MFX         52         18 - 60         400 mg, po, qd x 12d         65.4 (34/52)         92.3 (48/51)         93.3 (56/60)         96.6 (52)           2006         China         Urogential         MFX         52         18 - 60         400 mg, po, qd x 12d         65.4 (34/52)         92.3 (48/51)         93.3 (56/60)         96.6 (52)           2006         China         Urogential         MFX         52         10.4 (54/8) <th></th>											
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Sun GQ <sup>37</sup>	China	NGU	MFX	45 (26/19)	28.3 ± 11	400 mg, po, qd × 12 ~ 14d	75.0 (33/44)	93.2 (41/44)	91.8 (45/49)	18.2 (8/44)
$ \frac{R_{008}}{2006} + \frac{R_{0}}{2} + \frac{R_{0}}$	007	Uning	1100	AZI	41 (26/15)	27.36 ± 12	500 mg, po, qd × 12~14d	29.3 (12/41)	75.6 (31/41)	75.6 (31/41)	14.6 (6/41)
No.00         England         N.D.         OFLX/MT         365 (0/365)         30.5 ± 8.5         OFLX400 mg + MTZ500mg,po,bid x14d         90.7(26/289)         -         82.1 (46/56)         30.9(112/363)           Luo XM <sup>30</sup> China         UTI and RTI         MFX         56 (0/56)         27.6 ± 3.1         400mg,po,qdx12d         78.6 (44/56)         91.1(51/56)         -         73.2 (41/56)           Luo JL <sup>40</sup> China         Urogential infections         MFX         52         18 ~60         400 mg, po, qdx 14d         65.4 (34/52)         92.3 (48/51)         93.3 (56/60)         9.6 (5/52)           2006         China         Urogential infections         MFX         52         18 ~60         400 mg, po, qdx 14d         65.4 (34/52)         92.3 (48/51)         93.3 (56/60)         9.6 (5/52)           2006         China         Urogential infections         MFX         22         42.6 ± 10         Morning 400 mg + one placebo, evening two placebo, evening two placebo, evening two placebo, evening two placebo, evening two placebo, evening two placebo, po x 7-14d         84.2 (16/19)         100.0 (14/14)         65.0 (13/20)           Tian YP <sup>42</sup> China         Urogential infections         MFX         29 (41/17)         19 ~45         400 mg, po, qd x 7d         79.3 (23/29)         93.1 (27/29)         65.5 (19/29) <td>Ross<sup>38</sup></td> <td></td> <td>PID</td> <td>MFX</td> <td>384 (0/384)</td> <td>30.1 ± 8.4</td> <td>400 mg, po, qd × 14d</td> <td>90.2(248/275)</td> <td>-</td> <td>87.5 (49/85)</td> <td>22.5 (85/378)</td>	Ross <sup>38</sup>		PID	MFX	384 (0/384)	30.1 ± 8.4	400 mg, po, qd × 14d	90.2(248/275)	-	87.5 (49/85)	22.5 (85/378)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2006	England		OFLX/MT Z	365 (0/365)	30.5 ± 8.5	OFLX400 mg + MTZ500mg,po,bid ×14d	90.7(262/289)	-	82.1 (46/56)	30.9(112/363)
2006         China         UTrand RTI         DOX         56 (0/56)         27.5 ± 2.0         1 pill, po, bid x 14d         51.8 (29/56)         76.8(43/56)         -         73.2 (41/56)           Luo JL <sup>40</sup> China         Urogential infections         MFX         52         18 ~ 60         400 mg, po, dd x 14d         65.4 (34/52)         92.3 (48/51)         93.3 (56/60)         9.6 (5/52)           2006         China         Urogential infections         MFX         52         18 ~ 60         200 mg, po, bid x 14d         65.4 (34/52)         92.3 (48/51)         93.3 (56/60)         9.6 (5/52)           2007         China         UTI         MFX         22         42.6 ± 10         Morning 400 mg + one placebo, po x 7-14d         52.6 (10/19)         84.2 (16/19)         100.0 (14/14)         65.0 (13/20)           Tian YP <sup>42</sup> China         UTGential infections         MFX         22 (1/43)         43.5 ± 17.7         200 mg, po, bid x 7-14d         47.1 (8/17)         82.4 (14/17)         72.7 (8/11)         40.9 (9/22)           Tian YP <sup>42</sup> China         Urogential infections         MFX         29 (41/17)         19 ~ 45         400 mg, po, dd x 7d         79.3 (23/29)         93.1 (27/29)         89.7 (26/29)         55.2 (16/29)         56.2 (16/29)         56.6 (17/29)	Luo XM <sup>39</sup>	Ohina		MFX	56 (0/56)	27.6 ± 3.1	400mg,po,qd×12d	78.6 (44/56)	91.1(51/56)	-	12.5 (7/56)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2006	China	UIT and RIT	DOX	56 (0/56)	27.5 ± 2.0	1 pill, po, bid × 14d	51.8 (29/56)	76.8(43/56)	-	73.2 (41/56)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	ц		l luc acatici	MFX	52	18 ~ 60	400 mg, po, qd × 14d	65.4 (34/52)	92.3 (48/51)	93.3 (56/60)	9.6 (5/52)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		China	Urogential	GAT	50		200 mg, po, bid × 14d	64.0 (32/50)	90.0 (45/50)	88.5 (54/61)	10.0 (5/50)
$ \frac{Gao}{2005} HY^{41} \\ \frac{Gao}{2005} HY^{42} \\ \frac{Gao}{2005} HY^{42} \\ \frac{Gao}{2005} HY^{42} \\ \frac{Gao}{100} HY^$	2000		Intections	CPFX	48		200 mg, po, bid × 14d	41.7 (20/48)	64.6 (31/48)	57.9 (33/57)	10.4 (5/48)
$ \begin{array}{c} Gao \ HY^{41} \\ 2005 \end{array} \\ \begin{array}{c} China \\ 2005 \end{array} \\ \begin{array}{c} UTI \\ \\ UTI \\ \\ UVg \\ 2005 \end{array} \\ \begin{array}{c} WFX \\ 22 \ (1/43) \\ UVFX \\ 22 \ (1/43) \\ UVG \\ UVG \\ UVFX \\ 20 \ (1/17) \\ UVG \\ UVG \\ UVFX \\ UVG \\ UVFX \\ UVF$							Morning 400 mg + one				
$ \frac{1}{12005} \frac{1}{1200} \frac{1}{12000} \frac{1}{12000} \frac{1}{12000} \frac{1}{120000} \frac{1}{120000000000000000000000000000000000$	Gao HY <sup>41</sup> 2005	China	UTI	MFX	22	42.6 ± 10	placebo, evening two placebo, po × 7-14d	52.6 (10/19)	84.2 (16/19)	100.0 (14/14)	65.0 (13/20)
$ \frac{\text{Tian YP}^{42}}{2005}  \text{China}  \frac{\text{Urogential}}{\text{infections}}  \frac{\text{MFX}}{\text{TH}}  \begin{array}{c} 29 \ (41/17) \\ 29 \end{array}  \begin{array}{c} 19 \ - 45 \\ 29 \end{array}  \begin{array}{c} 400 \ \text{mg, po, qd x 7d} \\ 500 \ \text{mg, po, tid x 7d} \end{array}  \begin{array}{c} 79.3 \ (23/29) \\ 58.6 \ (17/29) \end{array}  \begin{array}{c} 93.1 \ (27/29) \\ 65.5 \ (19/29) \end{array}  \begin{array}{c} 89.7 \ (26/29) \\ 58.6 \ (17/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 62.2 \ (18/29) \end{array}  \begin{array}{c} 62.2 \ (18/29) \\ 65.1 \ (28/43) \end{array}  \begin{array}{c} 90.7 \ (39/43) \\ 90.7 \ (39/43) \end{array}  \begin{array}{c} 90.7 \ (39/43) \\ 88.4 \ (38/43) \end{array}  \begin{array}{c} 11.6 \ (5/43) \\ 16.3 \ (7/43) \end{array}  \begin{array}{c} 67.4 \ (29/43) \\ 16.3 \ (7/43) \end{array}  \begin{array}{c} 16.3 \ (7/43) \end{array}  \begin{array}{c} 67.4 \ (29/43) \\ 16.3 \ (7/43) \end{array}  \begin{array}{c} 16.3 \ (7/43) \\ 16.3 \ (7/43) \end{array}  \begin{array}{c} 77.2 \ (6/22) \\ 77.2 \ (6/22) \end{array}  \begin{array}{c} 67.4 \ (29/43) \\ 16.3 \ (7/43) \end{array}  \begin{array}{c} 77.2 \ (6/22) \\ 77.2 \ (6/22) \end{array}  \begin{array}{c} 67.4 \ (29/43) \\ 16.3 \ (7/43) \end{array}  \begin{array}{c} 77.2 \ (6/22) \\ 77.2 \ (6/22) \end{array}  \begin{array}{c} 77.2 \ (6/22) \end{array}  \begin{array}{c} 77.2 \ (6/22) \\ 77.2 \ (6/22) \end{array}  \begin{array}{c} 77.2 \ (6/2) \end{array}  \begin{array}{c} 77.2 \ (6/2) \end{array}  \begin{array}{c} 77.2 \ (7/2) \ $				LVFX	22 (1/43)	43.5 ± 17.7	200 mg, po, bid × 7-14d	47.1 (8/17)	82.4 (14/17)	72.7 (8/11)	40.9 (9/22)
2005ChinainfectionsTHI29 $500 \text{ mg}, \text{po}, \text{tid} \times 7d$ $58.6 (17/29)$ $65.5 (19/29)$ $58.6 (17/29)$ $62.2 (18/29)$ 2004MFX4343 $400 \text{ mg}, \text{po}, \text{qd} \times 14d$ $74.4 (32/43)$ $95.3 (41/43)$ $90.7 (39/43)$ $9.3 (4/43)$ 2004MFX43 (33/96)29.6200 mg, po, qd $\times 14d$ $65.1 (28/43)$ $90.7 (39/43)$ $88.4 (38/43)$ $11.6 (5/43)$ 2004MFX43200 mg, po, bid $\times 14d$ $53.5 (23/43)$ $69.8 (30/43)$ $67.4 (29/43)$ $16.3 (7/43)$ 2004MFX20 (1/19) $42 \pm 13$ Morning 400 mg + one placebo, evening two placebo, po $\times 7 - 14d$ $90.0 (8/20)$ $95.0 (19/20)$ $94.7 (18/19)$ $27.2 (6/22)$ LVFX20 (1/19) $42 \pm 14$ 200 mg, po, bid $\times 7 - 14d$ $85.0 (17/20)$ $90.0 (18/20)$ $100.0 (19/19)$ $27.2 (6/22)$	Tian YP <sup>42</sup>	Ohina	Urogential	MFX	29 (41/17)	19 ~ 45	400 mg, po, qd × 7d	79.3 (23/29)	93.1 (27/29)	89.7 (26/29)	55.2 (16/29)
Zhang WF <sup>43</sup> China       MFX       43       400 mg, po, qd x 14d       74.4 (32/43)       95.3 (41/43)       90.7 (39/43)       9.3 (4/43)         2004       Urogential mycoplasma infection       MFX       43 (33/96)       29.6       200 mg, po, qd x 14d       53.5 (23/43)       90.7 (39/43)       88.4 (38/43)       11.6 (5/43)         2004       Urogential mycoplasma infection       MFX       20 (1/19)       42 ± 13       Morning 400 mg + one placebo, evening two placebo, po x 7 - 14d       90.0 (8/20)       95.0 (19/20)       94.7 (18/19)       27.2 (6/22)         LVFX       20 (1/19)       42 ± 14       200 mg, po, bid x 7 - 14d       85.0 (17/20)       90.0 (18/20)       100.0 (19/19)       27.2 (6/22)	2005	China	infections	THI	29		500 mg, po, tid × 7d	58.6 (17/29)	65.5 (19/29)	58.6 (17/29)	62.2 (18/29)
Zhang WF <sup>43</sup> China       Urogential mycoplasma infection       SPFX       43 (33/96)       29.6       200 mg, po, qd x 14d       65.1 (28/43)       90.7 (39/43)       88.4 (38/43)       11.6 (5/43)         2004       WF <sup>43</sup> China       mycoplasma infection       MFX       20 (1/19)       42 ± 13       Morning 400 mg + one placebo, evening two placebo, po x 7 - 14d       90.0 (8/20)       95.0 (19/20)       94.7 (18/19)       27.2 (6/22)         LVFX       20 (1/19)       42 ± 14       200 mg, po, bid x 7 - 14d       85.0 (17/20)       90.0 (18/20)       100.0 (19/19)       27.2 (6/22)				MFX	43		400 mg, po, qd × 14d	74.4 (32/43)	95.3 (41/43)	90.7 (39/43)	9.3 (4/43)
Zhang WF <sup>43</sup> Urogential mycoplasma infection       LVFX       43       200 mg, po, bid x 14d       53.5 (23/43)       69.8 (30/43)       67.4 (29/43)       16.3 (7/43)         2004       Morning 400 mg + one infection       Morning 400 mg + one placebo, evening two placebo, po x 7 - 14d       90.0 (8/20)       95.0 (19/20)       94.7 (18/19)       27.2 (6/22)         LVFX       20 (1/19)       42 ± 14       200 mg, po, bid x 7 - 14d       85.0 (17/20)       90.0 (18/20)       100.0 (19/19)       27.2 (6/22)				SPFX	43 (33/96)	29.6	200 mg, po, qd × 14d	65.1 (28/43)	90.7 (39/43)	88.4 (38/43)	11.6 (5/43)
WF <sup>43</sup> China         mycoplasma           2004         infection         MFX         20 (1/19)         42 ± 13         placebo, evening two placebo, po x 7 - 14d         90.0 (8/20)         95.0 (19/20)         94.7 (18/19)         27.2 (6/22)           LVFX         20 (1/19)         42 ± 14         200 mg, po, bid x 7 - 14d         85.0 (17/20)         90.0 (18/20)         100.0 (19/19)         27.2 (6/22)	Zhang		Urogential	LVFX	43		200 mg, po, bid × 14d	53.5 (23/43)	69.8 (30/43)	67.4 (29/43)	16.3 (7/43)
2004         infection         MFX         20 (1/19)         42 ± 13         placebo, evening two placebo, po x 7 - 14d         90.0 (8/20)         95.0 (19/20)         94.7 (18/19)         27.2 (6/22)           LVFX         20 (1/19)         42 ± 14         200 mg, po, bid x 7 - 14d         85.0 (17/20)         90.0 (18/20)         100.0 (19/19)         27.2 (6/22)	WF <sup>43</sup>	China	mycoplasma				Manual 400 mar 1 and				
LVFX 20 (1/19) 42 ± 14 200 mg, po, bid × 7 - 14d 85.0 (17/20) 90.0 (18/20) 100.0 (19/19) 27.2 (6/22)	2004		infection	MFX	20 (1/19)	42 ± 13	placebo, evening two placebo, po $\times$ 7 - 14d	90.0 (8/20)	95.0 (19/20)	94.7 (18/19)	27.2 (6/22)
				LVFX	20 (1/19)	42 ± 14	200 mg, po, bid × 7 - 14d	85.0 (17/20)	90.0 (18/20)	100.0 (19/19)	27.2 (6/22)

MFX: Moxifloxacin; LVFX: levofloxacin; AZI: azithromycin; OFLX: ofloxacin; MTZ: metronidazole; SPFX: sparfloxacin; GAT: gatifloxacin; CTRX: ceftriaxon e sodium; CLA: clarithromycin; CPFX: ciprofloxacin; TRZ: terazosin; CAZ: ceftazidime; DOX: doxycycline; MINO: Minocycline; THI: thiamphenicol; UTI: urinary tract infections; NGU: non gonococcal urethritis; PID: pelvic inflammation disease; RTI: reproductive tract infection.

urinary tract infections (UTI), four pelvic inflammation disease (PID), five non-gonococcal urethritis (NGU), four urogenital infections and one reproductive tract infection (RTI).

Patients in the moxifloxacin group received moxifloxacin at dosage of 400 mg once a day (orally or intravenously), while the control group received the recommended dose of other antibiotics (according to different countries), such as levofloxacin, azithromycin, ofloxacin, metronidazole, sparfloxacin, gatifloxacin (sparfloxacin and gatifloxacin have been

Study ID	Randomization	Allocation concealment	Double blinding	Dropouts\withdraws	Jadad Grade
Zheng HZ 2010	Yes	Unclear	Unclear	No	В
Su XD 2010	Yes	Unclear	Unclear	No	В
Judlin 2010	Adequate	Yes	Yes	Yes	А
Meng W 2009	Yes	Unclear	Unclear	No	В
Dang JD 2009	Yes	Unclear	Unclear	No	В
Wang G 2009(a)	Yes	Unclear	Unclear	No	В
Wang G 2009(b)	Yes	Unclear	Unclear	No	В
Jin X 2009	Yes	Unclear	Unclear	No	В
Wang X 2009	Yes	Unclear	Unclear	No	В
Zhang YH 2009	Yes	Unclear	Unclear	No	В
Heystek 2009	Yes	Unclear	Yes	Yes	В
Li SQ 2008	Yes	Unclear	Unclear	No	В
Pei YH 2008	Yes	Unclear	Unclear	No	В
Zhang GH 2007	Yes	Unclear	Unclear	No	В
Sun GQ 2007	Yes	Unclear	Unclear	Yes	В
Ross 2006	Yes	Unclear	Yes	Yes	В
Luo XM 2006	Yes	Unclear	Unclear	No	В
Luo JL 2006	Yes	Unclear	Unclear	No	В
Gao HY 2005	Adequate	Unclear	Yes	Yes	В
Tian YP 2005	Yes	Unclear	Unclear	No	В
Zhang WF 2004	Yes	Unclear	Unclear	No	В
Cai SF 2003	Adequate	Unclear	Yes	No	В

Table 2. Quality assessment of included RCTs.

withdrawn from the American market, respectively, in 2005 due to QT prolongation and in 2006 due to dysglycemia). All patients included in the meta-analysis received antimicrobial treatment for a period of no less than seven days and a maximum of fourteen days.

The quality assessment of included RCTs is presented in Table 2. There studies clarified adequate randomization procedures, one reported allocation concealment, five used double blinding and five reported numbers of dropouts\withdrawals. One were eventually assessed to be good in terms of methodology with a Jadad score A (Juni et al., 2001), the other twenty-one were B.

# **Comparisons of effectiveness**

## Clinical success

All the twenty-two studies provided specific data for analysis of clinical cure. Clinical cure rate in the moxifloxacin group [1513 (77.7%) of 1947 patients] was higher than control group [1370 (72.91%) of 1879 patients], whilst statistically significant difference was found [RR = 1.08, 95%CI (1.02, 1.14), P = 0.008] (Figure 2).

19 studies (Zheng, 2010; Su et al., 2010; Meng et al., 2009; Tang et al., 2009; Wang et al., 2009a; Wang et al.,

2009b; Jin et al., 2009; Wang et al., 2009; Zhang et al., 2009; Li, 2008; Per et al., 2009; Zhang et al., 2007; Sun, 2007; Luo et al., 2006; Luo et al., 2006; Gao et al., 2005; Tian et al., 2005; Zhang et al., 2004; Cai et al., 2003) provided relevant data for analysis of clinical effectiveness which consisted of clinical cure and improvement. Clinical effective rate in the moxifloxacin group [1156 (92.9%) of 1244 patients] was higher than the control group [1035 (85.0%) of 1217 patients], while statistically significant difference was found [RR = 1.09, 95%CI (1.04, 1.14), P = 0.0005] (Figure 3).

## Microbiological treatment success

17 (Judin et al., 2010; Tang et al., 2009; Wang et al., 2009a; Wang et al., 2009b; Jin et al., 2009; Zhang et al., 2009; Heystek and Ross., 2009; Li, 2008; Per et al., 2009; Zhang et al., 2007; Sun, 2007; Ross et al., 2006; Luo JL et al., 2006; Gao et al., 2005; Tian et al., 2005; Zhang et al., 2004; Cai et al., 2003) of the 22 RCTs provided microbiological eradication data. 1088 (90.8%) of the 1198 patients in the moxifloxacin group and 1001 (86.5%) of the 1157 patients in the control group achieved eradication of the baseline pathogens. The overall pathogens eradication rate in the moxifloxacin group (90.8%, 1088/1198) was higher than control group (86.52%, 1001/1157), while statistically significant

	moxiflox	acin	conventional	therapy		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Cai SF 2003	18	20	17	20	3.7%	1.06 [0.84, 1.34]	· · · · · · · · · · · · · · · · · · ·
Gao HY 2005	10	19	8	17	0.7%	1.12 [0.58, 2.16]	· · · · · · · · · · · · · · · · · · ·
Heystek2009	224	232	198	202	10.1%	0.99 [0.95, 1.02]	· +
Jin X 2009	113	121	112	121	9.0%	1.01 [0.94, 1.08]	· +-
Judlin 2010	152	194	155	190	7.9%	0.96 [0.87, 1.06]	<b>_</b> ₽ <u></u> <u>+</u> _
Li SQ 2008	85	90	74	86	7.9%	1.10 [0.99, 1.21]	ı <b>⊢</b>
Luo JL 2006(1)	34	52	32	50	2.8%	1.02 [0.77, 1.36]	· · · · · · · · · · · · · · · · · · ·
Luo JL 2006(2)	34	52	20	48	1.7%	1.57 [1.06, 2.31]	· · · · ·
Luo XM 2006	44	56	29	56	2.8%	1.52 [1.14, 2.02]	· · · · · · · · · · · · · · · · · · ·
Meng W 2009	23	25	20	25	3.8%	1.15 [0.92, 1.44]	·
Pei YH 2008	41	62	20	31	2.4%	1.02 [0.75, 1.41]	· · · · · · · · · · · · · · · · · · ·
Ross2006	248	275	262	289	9.6%	0.99 [0.94, 1.05]	· +
Su XD 2010	24	60	20	60	1.2%	1.20 [0.75, 1.93]	· · · · · · · · · · · · · · · · · · ·
Sun GQ 2007	33	44	12	41	1.1%	2.56 [1.55, 4.25]	
Tang JD 2009	43	50	42	50	5.5%	1.02 [0.87, 1.21]	·
Tian YP2005	23	29	17	29	2.0%	1.35 [0.95, 1.94]	· · · · · · · · · · · · · · · · · · ·
Wang G2009 (a1)	45	80	44	80	3.0%	1.02 [0.78, 1.35]	·
Wang G2009 (a2)	45	80	46	80	3.1%	0.98 [0.75, 1.28]	· · · · · · · · · · · · · · · · · · ·
Wang G2009 (b)	90	150	84	149	4.7%	1.06 [0.88, 1.29]	·
Wang X2009	38	60	29	60	2.3%	1.31 [0.95, 1.81]	· · · · · · · · · · · · · · · · · · ·
Zhang GH 2007	23	38	24	38	2.0%	0.96 [0.67, 1.36]	· · · · ·
Zhang WF 2004(1)	32	43	28	43	2.9%	1.14 [0.86, 1.51]	· · · · · · · · · · · · · · · · · · ·
Zhang WF 2004(2)	32	43	23	43	2.3%	1.39 [1.00, 1.93]	· · · · ·
Zhang YH 2009	35	40	34	40	5.2%	1.03 [0.86, 1.23]	· · · · · · · · · · · · · · · · · · ·
Zheng HZ 2010	24	32	20	31	2.3%	1.16 [0.84, 1.62]	
Total (95% CI)		1947		1879	100.0%	1.08 [1.02, 1.14]	<b>•</b>
Total events	1513		1370				
Heterogeneity: Tau <sup>2</sup> =	0.01; Chi <sup>2</sup>	= 67.49,	df = 24 (P < 0.0	0001); l² =	64%		
Test for overall effect:	Z = 2.67 (F	• = 0.008	3)				0.5 0.7 1 1.5

Figure 2.	Meta-analy	sis of	cure rates	of moxifle	oxacin a	and c	onventional	therapy.
<u> </u>								

Study or Subgroup         Events         Total         Events         Total         Weight         M-H, Random, 95% Cl         M-H, Random, 95% Cl           Cai SF 2003         19         20         18         20         3.8%         1.06 [0.88, 1.26]		moxiflox	acin	conventional th	nerapy		Risk Ratio	Risk Ratio
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Gao HY 2005       16       19       14       17       2.0%       1.02 [0.76, 1.37]         Jin X 2009       115       121       116       121       7.2%       0.99 [0.94, 1.05]         Li SQ 2008       88       90       79       86       6.8%       1.06 [0.99, 1.14]         Luo JL 2006(1)       48       51       45       50       5.5%       1.05 [0.33, 1.17]         Luo JL 2006(2)       48       51       31       48       3.0%       1.46 [1.17, 1.82]         Luo XM 2006       51       56       43       56       4.1%       1.19 [1.00, 1.40]         Meng W 2009       25       25       24       25       5.6%       1.04 [0.93, 1.16]         Pei YH 2008       57       62       31       50       2.8%       1.48 [1.18, 1.86]         Su XD 2010       54       60       43       60       3.7%       1.26 [1.05, 1.50]         Sun GQ 2007       41       44       31       41       3.5%       1.02 [0.91, 1.6]         Tang JD 2009       46       50       45       50       5.2%       1.02 [0.91, 1.6]         Wang G2009 (a1)       73       80       73       80       6.3%       0.97	Cai SF 2003	19	20	18	20	3.8%	1.06 [0.88, 1.26]	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Gao HY 2005	16	19	14	17	2.0%	1.02 [0.76, 1.37]	
Li SQ 2008 88 90 79 86 6.8% 1.06 [0.99, 1.14] Luo JL 2006(1) 48 51 45 50 5.5% 1.05 [0.33, 1.17] Luo JL 2006(2) 48 51 31 48 3.0% 1.46 [1.17, 1.82] Luo XM 2006 51 56 43 56 4.1% 1.19 [1.00, 1.40] Meng W 2009 25 25 24 25 5.6% 1.04 [0.93, 1.16] Pei YH 2008 57 62 31 50 2.8% 1.48 [1.18, 1.86] Su XD 2010 54 60 43 60 3.7% 1.26 [1.05, 1.50] Sun GQ 2007 41 44 31 41 3.5% 1.23 [1.02, 1.49] Tang JD 2009 46 50 45 50 5.2% 1.02 [0.90, 1.16] Tian YP2005 27 29 19 29 2.1% 1.42 [1.07, 1.88] Wang G2009 (a1) 73 80 73 80 6.0% 1.00 [0.91, 1.10] Wang G2009 (a2) 73 80 75 80 6.3% 0.97 [0.88, 1.06] Wang G2009 (b) 144 150 142 149 7.4% 1.01 [0.96, 1.06] Wang S2009 49 60 39 60 2.9% 1.26 [1.01, 1.57] Zhang GH 2007 33 38 34 38 4.1% 0.97 [0.82, 1.14] Zhang WF 2004(1) 41 43 39 43 5.4% 1.05 [0.94, 1.18] Zhang WF 2004(2) 41 43 30 43 3.2% 1.37 [1.11, 1.68] Zhang YH 2009 38 40 37 40 5.5% 1.03 [0.92, 1.15] Zheng HZ 2010 29 32 27 31 3.8% 1.04 [0.87, 1.24] Total events 1156 1035 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); P = 69% Total events 1156 0.005	Jin X 2009	115	121	116	121	7.2%	0.99 [0.94, 1.05]	+
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Li SQ 2008	88	90	79	86	6.8%	1.06 [0.99, 1.14]	-
Luo JL 2006(2) 48 51 31 48 3.0% 1.46 [1.17, 1.82] Luo XM 2006 51 56 43 56 4.1% 1.19 [1.00, 1.40] Meng W 2009 25 25 24 25 5.6% 1.04 [0.93, 1.16] Pei YH 2008 57 62 31 50 2.8% 1.48 [1.18, 1.86] Su XD 2010 54 60 43 60 3.7% 1.26 [1.05, 1.50] Sun GQ 2007 41 44 31 41 3.5% 1.23 [1.02, 1.49] Tang JD 2009 46 50 45 50 5.2% 1.02 [0.90, 1.16] Tian YP2005 27 29 19 29 2.1% 1.42 [1.07, 1.88] Wang G2009 (a1) 73 80 73 80 6.0% 1.00 [0.91, 1.10] Wang G2009 (b) 144 150 142 149 7.4% 1.01 [0.96, 1.06] Wang G2009 (b) 144 150 142 149 7.4% 1.01 [0.96, 1.06] Wang G2009 (b) 144 150 142 149 7.4% 1.01 [0.96, 1.06] Wang C2009 (b) 144 33 39 43 5.4% 1.05 [0.94, 1.18] Zhang WF 2004(1) 41 43 39 43 5.4% 1.05 [0.94, 1.18] Zhang WF 2004(2) 41 43 30 43 3.2% 1.37 [1.11, 1.68] Zhang YH 2009 38 40 37 40 5.5% 1.03 [0.92, 1.15] Zheng HZ 2010 29 32 27 31 3.8% 1.04 [0.87, 1.24] Total (95% CI) 124 1217 100.0% 1.09 [1.04, 1.14] Total (95% CI) 124 (1217 100.0% 1.09 [1.04, 1.14] Total events 1156 1035 Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); I <sup>2</sup> = 69% Test for overall effect: Z = 3.46 (P = 0.0005)	Luo JL 2006(1)	48	51	45	50	5.5%	1.05 [0.93, 1.17]	
Luo XM 2006515643564.1% $1.19 [1.00, 1.40]$ Meng W 2009252524255.6% $1.04 [0.93, 1.16]$ Pei YH 2008576231502.8% $1.48 [1.18, 1.86]$ Su XD 201054604360 $3.7\%$ $1.26 [1.05, 1.50]$ Sun GQ 200741443141 $3.5\%$ $1.23 [1.02, 1.49]$ Tang JD 200946504550 $5.2\%$ $1.02 [0.90, 1.16]$ Tian YP200527291929 $2.1\%$ $1.42 [1.07, 1.88]$ Wang G2009 (a1)73807580 $6.3\%$ $0.97 [0.89, 1.06]$ Wang G2009 (b)144150142149 $7.4\%$ $1.01 [0.96, 1.06]$ Wang G2009 (b)144150142149 $7.4\%$ $1.05 [0.94, 1.16]$ Wang G2009 (b)144133943 $5.4\%$ $1.05 [0.94, 1.18]$ Zhang WF 2004(2)41433043 $3.2\%$ $1.37 [1.11, 1.68]$ Zhang YH 200938403740 $5.5\%$ $1.03 [0.92, 1.15]$ Zhang YH 200938403740 $5.5\%$ $1.09 [1.04, 1.14]$ Total (95% CI)12441217 $100.0\%$ $1.09 [1.04, 1.14]$ Total events1156 $1035$ $0.7$ $1.5$ Heterogeneity: Tau² = $0.01$ ; Chi² = $68.35$ , df = $21 (P < 0.00001)$ ; $i² = 69\%$ $0.5$ $0.7$ $1.5$ Test for overall effect: Z = $3.46 (P = 0.0005)$ </td <td>Luo JL 2006(2)</td> <td>48</td> <td>51</td> <td>31</td> <td>48</td> <td>3.0%</td> <td>1.46 [1.17, 1.82]</td> <td></td>	Luo JL 2006(2)	48	51	31	48	3.0%	1.46 [1.17, 1.82]	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Luo XM 2006	51	56	43	56	4.1%	1.19 [1.00, 1.40]	
Pei YH 2008       57       62       31       50       2.8%       1.48 [1.18, 1.86]         Su XD 2010       54       60       43       60       3.7%       1.26 [1.05, 1.50]         Sun GQ 2007       41       44       31       41       3.5%       1.23 [1.02, 1.49]         Tang JD 2009       46       50       45       50       5.2%       1.02 [0.90, 1.16]         Tian YP2005       27       29       19       29       2.1%       1.42 [1.07, 1.88]         Wang G2009 (a1)       73       80       73       80       6.3%       0.97 [0.89, 1.06]         Wang G2009 (b)       144       150       142       149       7.4%       1.01 [0.96, 1.06]         Wang X2009       49       60       39       60       2.9%       1.26 [1.01, 1.57]         Zhang GH 2007       33       38       34       38       4.1%       0.97 [0.82, 1.14]         Zhang WF 2004(1)       41       43       30       43       3.2%       1.37 [1.11, 1.68]         Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]	Meng W 2009	25	25	24	25	5.6%	1.04 [0.93, 1.16]	
Su XD 2010       54       60       43       60       3.7%       1.26 [1.05, 1.50]         Sun GQ 2007       41       44       31       41       3.5%       1.23 [1.02, 1.49]         Tang JD 2009       46       50       45       50       5.2%       1.02 [0.90, 1.16]         Tian YP2005       27       29       19       29       2.1%       1.42 [1.07, 1.88]         Wang G2009 (a1)       73       80       73       80       6.0%       1.00 [0.91, 1.10]         Wang G2009 (a2)       73       80       75       80       6.3%       0.97 [0.89, 1.06]         Wang G2009 (b)       144       150       142       149       7.4%       1.01 [0.96, 1.06]         Wang X2009       49       60       39       60       2.9%       1.26 [1.01, 1.57]         Zhang GH 2007       33       38       34       38       4.1%       0.97 [0.82, 1.14]         Zhang WF 2004(1)       41       43       30       43       3.2%       1.37 [1.11, 1.68]         Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]       40         Total (95% CI)       1244       1217       100.0%	Pei YH 2008	57	62	31	50	2.8%	1.48 [1.18, 1.86]	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Su XD 2010	54	60	43	60	3.7%	1.26 [1.05, 1.50]	
Tang JD 2009465045505.2%1.02 [0.90, 1.16]Tian YP2005272919292.1%1.42 [1.07, 1.88]Wang G2009 (a1)738073806.0%1.00 [0.91, 1.10]Wang G2009 (a2)738075806.3%0.97 [0.89, 1.06]Wang G2009 (b)1441501421497.4%1.01 [0.96, 1.06]Wang X2009496039602.9%1.26 [1.01, 1.57]Zhang GH 2007333834384.1%0.97 [0.82, 1.14]Zhang WF 2004(1)414339435.4%1.05 [0.94, 1.18]Zhang WF 2004(2)414330433.2%1.37 [1.11, 1.68]Zhang YH 2009384037405.5%1.03 [0.92, 1.15]Zheng HZ 2010293227313.8%1.04 [0.87, 1.24]Total (95% CI)12441217100.0%1.09 [1.04, 1.14]Total events11561035Heterogeneity: Tau² = 0.01; Chi² = 68.35, df = 21 (P < 0.00001); I² = 69%	Sun GQ 2007	41	44	31	41	3.5%	1.23 [1.02, 1.49]	
Tian YP2005272919292.1%1.42 [1.07, 1.88]Wang G2009 (a1)738073806.0%1.00 [0.91, 1.10]Wang G2009 (a2)738075806.3%0.97 [0.89, 1.06]Wang G2009 (b)1441501421497.4%1.01 [0.96, 1.06]Wang G2009496039602.9%1.26 [1.01, 1.57]Zhang GH 2007333834384.1%0.97 [0.82, 1.14]Zhang WF 2004(1)414339435.4%1.05 [0.94, 1.18]Zhang WF 2004(2)414330433.2%1.37 [1.11, 1.68]Zhang YH 2009384037405.5%1.03 [0.92, 1.15]Zheng HZ 2010293227313.8%1.04 [0.87, 1.24]Total (95% CI)12441217100.0%1.09 [1.04, 1.14]Total events11561035Heterogeneity: Tau² = 0.01; Chi² = 68.35, df = 21 (P < 0.00001); l² = 69%	Tang JD 2009	46	50	45	50	5.2%	1.02 [0.90, 1.16]	
Wang G2009 (a1)       73       80       73       80       6.0%       1.00 [0.91, 1.10]         Wang G2009 (a2)       73       80       75       80       6.3%       0.97 [0.89, 1.06]         Wang G2009 (b)       144       150       142       149       7.4%       1.01 [0.96, 1.06]         Wang X2009       49       60       39       60       2.9%       1.26 [1.01, 1.57]         Zhang GH 2007       33       38       34       38       4.1%       0.97 [0.82, 1.14]         Zhang WF 2004(1)       41       43       39       43       5.4%       1.05 [0.94, 1.18]         Zhang WF 2004(2)       41       43       30       43       3.2%       1.37 [1.11, 1.68]         Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]         Zheng HZ 2010       29       32       27       31       3.8%       1.04 [0.87, 1.24]         Total (95% CI)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Use tor o	Tian YP2005	27	29	19	29	2.1%	1.42 [1.07, 1.88]	· · · · · · · · · · · · · · · · · · ·
Wang G2009 (a2)       73       80       75       80 $6.3\%$ $0.97 [0.89, 1.06]$ Wang G2009 (b)       144       150       142       149       7.4%       1.01 [0.96, 1.06]         Wang X2009       49       60       39       60       2.9%       1.26 [1.01, 1.57]         Zhang GH 2007       33       38       34       38       4.1%       0.97 [0.82, 1.14]         Zhang WF 2004(1)       41       43       39       43       5.4%       1.05 [0.94, 1.18]         Zhang WF 2004(2)       41       43       30       43       3.2%       1.37 [1.11, 1.68]         Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]         Zheng HZ 2010       29       32       27       31       3.8%       1.04 [0.87, 1.24]         Total (95% Cl)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005)       1000000000000000000000000000000000000	Wang G2009 (a1)	73	80	73	80	6.0%	1.00 [0.91, 1.10]	-+-
Wang G2009 (b)       144       150       142       149       7.4%       1.01 [0.96, 1.06]         Wang X2009       49       60       39       60       2.9%       1.26 [1.01, 1.57]         Zhang GH 2007       33       38       34       38       4.1%       0.97 [0.82, 1.14]         Zhang WF 2004(1)       41       43       39       43       5.4%       1.05 [0.94, 1.18]         Zhang WF 2004(2)       41       43       30       43       3.2%       1.37 [1.11, 1.68]         Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]         Zheng HZ 2010       29       32       27       31       3.8%       1.04 [0.87, 1.24]         Total (95% Cl)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005)       1000000000000000000000000000000000000	Wang G2009 (a2)	73	80	75	80	6.3%	0.97 [0.89, 1.06]	
Wang X2009       49       60       39       60       2.9%       1.26 [1.01, 1.57]         Zhang GH 2007       33       38       34       38       4.1%       0.97 [0.82, 1.14]         Zhang WF 2004(1)       41       43       39       43       5.4%       1.05 [0.94, 1.18]         Zhang WF 2004(2)       41       43       30       43       3.2%       1.37 [1.11, 1.68]         Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]         Zheng HZ 2010       29       32       27       31       3.8%       1.04 [0.87, 1.24]         Total (95% Cl)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005)       1000000000000000000000000000000000000	Wang G2009 (b)	144	150	142	149	7.4%	1.01 [0.96, 1.06]	+
Zhang GH 2007       33       38       34       38       4.1% $0.97 [0.82, 1.14]$ Zhang WF 2004(1)       41       43       39       43       5.4% $1.05 [0.94, 1.18]$ Zhang WF 2004(2)       41       43       30       43 $3.2\%$ $1.37 [1.11, 1.68]$ Zhang YH 2009       38       40       37       40 $5.5\%$ $1.03 [0.92, 1.15]$ Zheng HZ 2010       29       32       27       31 $3.8\%$ $1.04 [0.87, 1.24]$ Total (95% Cl)       1244       1217       100.0% $1.09 [1.04, 1.14]$ Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69% $0.5$ $0.7$ Test for overall effect: Z = 3.46 (P = 0.0005) $1.5$ $0.5$ $0.7$ $1.5$ $2$	Wang X2009	49	60	39	60	2.9%	1.26 [1.01, 1.57]	
Zhang WF 2004(1)       41       43       39       43       5.4%       1.05 [0.94, 1.18]         Zhang WF 2004(2)       41       43       30       43       3.2%       1.37 [1.11, 1.68]         Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]         Zheng HZ 2010       29       32       27       31       3.8%       1.04 [0.87, 1.24]         Total (95% Cl)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005) $46 (P = 0.0005)$ $43 (P = 0.0005)$	Zhang GH 2007	33	38	34	38	4.1%	0.97 [0.82, 1.14]	
Zhang WF 2004(2)       41       43       30       43 $3.2\%$ $1.37$ [1.11, 1.68]         Zhang YH 2009       38       40       37       40 $5.5\%$ $1.03$ [0.92, 1.15]         Zheng HZ 2010       29       32       27       31 $3.8\%$ $1.04$ [0.87, 1.24]         Total (95% Cl)       1244       1217       100.0% $1.09$ [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69% $0.5$ $0.7$ $1$ $1.5$ 2         Test for overall effect: Z = 3.46 (P = 0.0005) $0.5$ $0.7$ $1$ $1.5$ $2$	Zhang WF 2004(1)	41	43	39	43	5.4%	1.05 [0.94, 1.18]	
Zhang YH 2009       38       40       37       40       5.5%       1.03 [0.92, 1.15]         Zheng HZ 2010       29       32       27       31       3.8%       1.04 [0.87, 1.24]         Total (95% Cl)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005)       0.0005       0.5       0.7       1       1.5       2	Zhang WF 2004(2)	41	43	30	43	3.2%	1.37 [1.11, 1.68]	
Zheng HZ 2010       29       32       27       31       3.8%       1.04 [0.87, 1.24]         Total (95% Cl)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005)       For events	Zhang YH 2009	38	40	37	40	5.5%	1.03 [0.92, 1.15]	
Total (95% Cl)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005) $   -$ <	Zheng HZ 2010	29	32	27	31	3.8%	1.04 [0.87, 1.24]	
Total (95% CI)       1244       1217       100.0%       1.09 [1.04, 1.14]         Total events       1156       1035         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); l <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: Z = 3.46 (P = 0.0005)       0.5       0.7       1       1.5       2								
Total events       1156       1035         Heterogeneity: $Tau^2 = 0.01$ ; Chi <sup>2</sup> = 68.35, df = 21 (P < 0.00001); I <sup>2</sup> = 69%       0.5       0.7       1       1.5       2         Test for overall effect: $Z = 3.46$ (P = 0.0005)       1       1.5       2	Total (95% CI)		1244		1217	100.0%	1.09 [1.04, 1.14]	$\bullet$
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 68.35, df = 21 (P < $0.00001$ ); l <sup>2</sup> = 69% Test for overall effect: Z = 3.46 (P = $0.0005$ )	Total events	1156		1035				
Test for overall effect: Z = 3.46 (P = 0.0005)	Heterogeneity: Tau <sup>2</sup> =	0.01; Chi² :	= 68.35,	df = 21 (P < 0.00	0001); l² =	= 69%		
Eavours conventional Eavours movifioxacin	Test for overall effect:	Z = 3.46 (P	= 0.000	05)				Favours conventional Favours movifloxacin

Figure 3. Meta-analysis of clinical effective rates of moxifloxacin and conventional therapy.

difference was found [RR = 1.04, 95% (0.99, 1.09), P=0.08] (Figure 4).

# Comparisons of safety

All of the twenty-two RCTs provided adverse drug reaction data. In the total evaluable population, the incidence of adverse drug reaction between moxifloxacin group [509 (23.8%) of the 2136 patients] and control group [580 (27.9%) of the 2077 patients] had no statistically significant difference [RR = 0.88, 95%CI (0.72, 1.06), P = 0.17] (Figure 5).

# **Comparisons of PID patients**

Judin (Judin et al., 2010), Heystek (Heystek et al., 2009) and Ross (Ross et al., 2006) altogether researched 1643 pelvic inflammatory disease (PID) patients. As the their studies recommended moxifloxacin as first-line therapy for pelvic inflammatory disease, we exclusively performed a meta-analysis for them. For the primary measure of efficacy [clinical cure rate at test-of-cure (TOC)], moxifloxacin was non-inferior to comparator (moxifloxacin: 624/701, 89.0%; comparator: 615/681, 90.3%) with no statistically significant difference between moxifloxacin and control group [RR = 0.98, 95%Cl (0.95, 1.02), P = 0.33] (Figure 6). Microbiological success rates were 90.2% (119/132) for moxifloxacin and 85.1% (103/121) for comparator, whilst no statistically significant difference was found [RR = 1.06, 95%CI (0.96, 1.16), P = 0.25] (Figure 7). No statistically significant difference was found [RR = 0.85, 95%CI (0.68, 1.05), P = 0.13] (Figure 8) between moxifloxacin [38.5% (315/949)] versus the comparator [45.9% (406/884)] about adverse drug reaction rates.

# DISCUSSION

We conducted this meta-analysis to compare the efficacy and safety of moxifloxacin monotherapy with conventional antimicrobial therapy for urogenital system infections. The overall RR of clinical rate, clinical effective rate and pathogens eradication rate of moxifloxacin were higher than control group. The results of meta-analysis indicated that efficacy of moxifloxacin was superior to conventional antibiotics therapy with statistically significant difference [Clinical cure rate: RR = 1.08, 95%CI (1.02, 1.14), P = 0.008; clinical effective rate: RR = 1.09, 95%CI (1.04, 1.14), P = 0.0005; pathogens eradication rate: RR = 1.04, 95% (0.99, 1.09), P = 0.08]. The safety profile analysis regarding the incidence of adverse drug reactions had no significant difference between moxifloxacin and control group [RR = 0.88, 95%Cl (0.72, 1.06), P = 0.17]. Moreover, the efficacy and safety profile for PID patients (Judin, 2010; Heystek, 2009; Ross, 2006) were separately analyzed. These three large randomized controlled trials supported the efficacy of moxifloxacin for the treatment of uncomplicated PID. Clinical cure rates observed in the MONALISA (Judin et al., 2010) study were 78.4% for moxifloxacin versus 81.6% for levofloxacin plus metronidazole. Heysteck (2009) reported a clinical cure rate of 81.5% in women treated with moxifloxacin versus 83.2% in those treated with the doxycycline plus metronidazole plus one dose of ciprofloxacin. In the MAIDEN (Ross et al., 2006) study, clinical cure rate was achieved in 90.2% for moxifloxacin versus 90.7% for ofloxacin plus metronidazole. Meta-analysis indicated that the difference of efficacy between moxifloxacin monotherapy group and combination therapy group was not statistically significant (Clinical cure rates: RR = 0.98, 95%CI (0.95, 1.02), P = 0.33). In addition, no statistically significant differences were found in pathogens eradication rates (RR = 1.06, 95%CI (0.96, 1.16), P = 0.25) and the incidences of adverse drug reactions (RR = 0.85, 95%CI (0.68, 1.05), p = 0.13). Moxifloxacin monotherapy, 400 mg once daily for 14 days, is an effective and well-tolerated treatment for women with PID. Therefore, moxifloxacin can be recommended as the first-line therapy for uncomplicated PID.

In all the included studies, moxifloxacin had the advantage of using single dose per day and did not need combination because of broad coverage to pathogens. greater Monotherapy is always associated with compliance than combination therapy (Haggerty and Ness, 2007), especially for outpatients. The administration of moxifloxacin was intravenous or oral and its medication time was free from diet (Instruction of Moxifloxacin Hydrochloride Tablets). Moxifloxacin can be accessible to inpatients and outpatients with greater compliance. The most common adverse events reported in the included studies were gastrointestinal disturbances and central nervous system reactions, such as nausea, diarrhea, vomiting, dizzy and headache. Serious adverse events were not reported in the enrolled articles. Balfour et al. (1999) demonstrated that in contrast to some other fluoroquinolones, moxifloxacin appears to have a low propensity for causing phototoxic and central nervous system (CNS) excitatory effects, and the most common adverse events are gastrointestinal disturbances.

This meta-analysis is not without limitations. Certain limitations affecting the results of this meta-analysis should be taken into account. Firstly, our findings may be affected by the quality of trials included in the meta-analysis. Only five of the included trials were double blinding, and only three clarified adequate randomization procedures. A sensitivity analysis was performed including only trials that were double-blinded, the comparisons of pathogens eradication rates and incidence of adverse drug reaction were consistent with the primary results. The primary clinical effective rate of moxifloxacin was superiority to conventional antibiotics

	moxiflox	acin	conventional t	herapy		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Cai SF 2003	18	19	19	19	5.1%	0.95 [0.82, 1.09]	
Gao HY 2005	14	14	8	11	1.3%	1.36 [0.94, 1.99]	
Heystek2009	43	46	35	39	5.6%	1.04 [0.91, 1.19]	
Jin X 2009	116	121	117	121	8.9%	0.99 [0.94, 1.04]	+
Judlin 2010	27	30	22	26	3.4%	1.06 [0.87, 1.30]	
Li SQ 2008	87	90	81	86	8.3%	1.03 [0.96, 1.10]	
Luo JL 2006(1)	56	60	54	61	6.3%	1.05 [0.94, 1.18]	
Luo JL 2006(2)	56	60	33	57	2.9%	1.61 [1.28, 2.03]	
Pei YH 2008	51	57	32	44	3.5%	1.23 [1.01, 1.51]	
Ross2006	49	56	46	56	4.6%	1.07 [0.91, 1.25]	
Sun GQ 2007	45	49	31	41	3.7%	1.21 [1.00, 1.47]	
Tang JD 2009	43	47	42	46	5.8%	1.00 [0.88, 1.14]	
Tian YP2005	19	29	29	29	2.3%	0.66 [0.51, 0.86]	
Wang G2009 (a1)	72	80	73	80	6.8%	0.99 [0.89, 1.09]	
Wang G2009 (a2)	72	80	74	80	7.0%	0.97 [0.88, 1.07]	
Wang G2009 (b)	169	188	162	186	8.0%	1.03 [0.96, 1.11]	- <b>-</b>
Zhang GH 2007	42	46	46	50	5.9%	0.99 [0.88, 1.12]	
Zhang WF 2004(1)	39	43	38	43	5.1%	1.03 [0.89, 1.19]	
Zhang WF 2004(2)	39	43	29	43	2.9%	1.34 [1.07, 1.69]	
Zhang YH 2009	31	40	30	39	2.7%	1.01 [0.79, 1.28]	
Total (95% CI)		1198		1157	100.0%	1.04 [0.99, 1.09]	<b>◆</b>
Total events	1088		1001				
Heterogeneity: Tau <sup>2</sup> =	0.01; Chi <sup>2</sup>	= 49.43,	df = 19 (P = 0.0	002); l <sup>2</sup> = 6	62%		
Test for overall effect:	Z = 1.74 (F	9 = 0.08)	)				U.5 U.7 I 1.5 2
							r avours conventional Favours moximoxacin

Figure 4. Meta-analysis of pathogens eradication rates of moxifloxacin and conventional therapy.

	moxiflox	acin	conventional t	herapy		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Cai SF 2003	16	22	6	22	4.6%	2.67 [1.29, 5.53]	
Gao HY 2005	13	20	9	22	5.9%	1.59 [0.88, 2.88]	+
Heystek2009	151	343	162	326	12.9%	0.89 [0.75, 1.04]	
Jin X 2009	11	121	11	121	4.1%	1.00 [0.45, 2.22]	
Judlin 2010	129	228	132	232	13.0%	0.99 [0.85, 1.17]	+
Li SQ 2008	7	90	8	86	3.0%	0.84 [0.32, 2.21]	
Luo JL 2006(1)	5	52	7	32	2.6%	0.44 [0.15, 1.27]	
Luo JL 2006(2)	5	52	5	48	2.2%	0.92 [0.28, 2.99]	
Luo XM 2006	7	56	41	56	4.8%	0.17 [0.08, 0.35]	←
Meng W 2009	4	25	8	25	2.6%	0.50 [0.17, 1.45]	
Ross2006	85	378	112	363	11.6%	0.73 [0.57, 0.93]	
Su XD 2010	4	60	6	60	2.1%	0.67 [0.20, 2.24]	
Sun GQ 2007	8	44	6	41	3.0%	1.24 [0.47, 3.27]	
Tang JD 2009	3	50	3	50	1.4%	1.00 [0.21, 4.72]	
Tian YP2005	16	29	18	29	8.2%	0.89 [0.58, 1.37]	
Wang G2009 (a1)	8	80	5	80	2.6%	1.60 [0.55, 4.68]	
Wang G2009 (a2)	8	80	9	80	3.4%	0.89 [0.36, 2.19]	
Wang G2009 (b)	12	150	13	149	4.4%	0.92 [0.43, 1.94]	
Wang X2009	3	60	0	60	0.4%	7.00 [0.37, 132.66]	
Zhang GH 2007	1	38	2	38	0.6%	0.50 [0.05, 5.28]	· · · ·
Zhang WF 2004(1)	4	43	5	43	2.0%	0.80 [0.23, 2.78]	
Zhang WF 2004(2)	4	43	7	43	2.3%	0.57 [0.18, 1.81]	
Zhang YH 2009	2	40	3	40	1.1%	0.67 [0.12, 3.78]	· · · · ·
Zheng HZ 2010	3	32	2	31	1.1%	1.45 [0.26, 8.11]	
Total (95% CI)		2136		2077	100.0%	0.88 [0.72, 1.06]	•
Total events	509		580				
Heterogeneity: Tau <sup>2</sup> = 0	0.07; Chi² :	= 46.31,	df = 23 (P = 0.00	03); l <sup>2</sup> = 50	0%		
Test for overall effect: Z	Z = 1.37 (P	9 = 0.17)					0.10.20.512510Favours moxifloxacinFavours conventional

Figure 5. Meta-analysis of the incidences of adverse drug reactions of moxifloxacin and conventional therapy.

	Experim	ental	Contr	ol		Risk Ratio		R	isk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I	М-Н,	Fixed, 95%	∕₀ CI	
Heystek2009	224	232	198	202	33.9%	0.99 [0.95, 1.02]			•		
Judlin 2010	152	194	155	190	25.1%	0.96 [0.87, 1.06]		-			
Ross2006	248	275	262	289	41.0%	0.99 [0.94, 1.05]			+		
Total (95% CI)		701		681	100.0%	0.98 [0.95, 1.02]			•		
Total events	624		615								
Heterogeneity: Chi <sup>2</sup> = 0.42, df = 2 (P = 0.81); l <sup>2</sup> = 0%								0.7		4.5	-
Test for overall effect: $Z = 0.97$ (P = 0.33)							0.5 Favou	0.7 rs conventio	nal Favo	1.5 urs moxiflox	2 acin

Figure 6. Meta-analysis of clinical cure rates of moxifloxacin and conventional therapy in the three PID studies.

	Experim	ental	Contr	ol		<b>Risk Ratio</b>			Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C			<u>M-H, Fix</u>	ed, 95%	CI	
Heystek2009	43	46	35	39	35.3%	1.04 [0.91, 1.19]						
Judlin 2010	27	30	22	26	21.9%	1.06 [0.87, 1.30]					_	
Ross2006	49	56	46	56	42.8%	1.07 [0.91, 1.25]				╞		
Total (95% CI)		132		121	100.0%	1.06 [0.96, 1.16]			•			
Total events	119		103									
Heterogeneity: Chi <sup>2</sup> = 0	0.06, df = 2	(P = 0.9	97); l² = 0	%				07		1	1.5	
Test for overall effect: 2				0.5 Favoi	U.7 Jrs conv	entional	Favou	rs moxiflox	∠ acin			

Figure 7. Meta-analysis of microbiological success rates of moxifloxacin and conventional therapy in the three PID studies.

	Experim	ental	Contr	ol	Risk Ratio			Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C		М-Н,	Random, 9	5% CI	
Heystek2009	151	343	162	326	35.5%	0.89 [0.75, 1.04]			•		
Judlin 2010	129	228	132	232	35.7%	0.99 [0.85, 1.17]					
Ross2006	85	378	112	326	28.8%	0.65 [0.51, 0.83]		-			
Total (95% CI)		949		884	100.0%	0.85 [0.68, 1.05]					
Total events	365		406								
Heterogeneity: Tau <sup>2</sup> =	0.03; Chi² :	= 8.44, c	df = 2 (P =	= 0.01);	l² = 76%						
Test for overall effect:	Z = 1.50 (P = 0.13)							0.7 urs moxiflox	1 acin Favo	1.5 ours convent	2 ional

Figure 8. Meta-analysis of the incidence of adverse reaction of moxifloxacin and conventional therapy in the three PID studies.

therapy with statistically significant difference, but not finding statistically significant difference at sensitivity analysis. Secondly, heterogeneity was found among the included trials, we cannot make symmetrical funnel plots. Publication bias can lead to overestimation in meta-analysis. The funnel plot is frequently used to detect publication bias which can lead to overestimation in meta-analysis (Souza et al., 2007). However, heterogeneity does not preclude pooling of the results because individual patients are directly compared only with other patients within the same trial, and not across trials (Lau et al., 1998; Thompson, 1994) Although some limitations exist in this meta-analysis, we believe that moxifloxacin can be considered using for the treatment of urogenital infections for the following reasons. First, the results of this meta-analysis revealed that the clinical cure rate and clinical effective rate achieved with moxifloxacin tended to be higher than obtained in the groups that received conventional antibiotic treatment and the incidence of adverse drug reactions of moxifloxacin was not significantly different from the control group. Second, the compliance of patients is influenced by the complexity of the dosage regimen. The simple usage of moxifloxacin (400 mg, once a day, PO/IV) offer benefits compared with regimens that require combination therapy or multiple dosing. Moreover, it does not need to adjust the dosage of moxifloxacin for elderly patients and those patients with renal or mild hepatic impairment (Ball et al., 2004). Third, in a review article, Bambeke et al. (Van and Tulkens, 2009) concluded that moxifloxacin did not reveal significantly higher incidences of drug-related adverse effects than for comparators. It was coincident with result of this meta-analysis. Certainly, further high quality RCTs are required.

#### REFERENCES

Balfour JA, Wiseman LR (1999). Moxifloxacin, Drugs, 57(3): 363-374.

- Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R (2004). Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies, Clin. Ther., 26(7): 940-950.
- Bebear CM, Barbeyrac B, Pereyre S, Renaudin H, Clerc M, Bebear C (2008). Activity of moxifloxacin against the urogenital mycoplasmas *Ureaplasma* spp., *Mycoplasma hominis* and *Mycoplasma genitalium* and *Chlamydia trachomatis*, Clin. Microbiol. Infect.,14(8): 801-805.
- Boswell FJ, Andrews JM, Jevons G, Wise R (2002). Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance, J. Antimicrob. Chemother., 50(4): 495-502.
- Brueggemann AB, Kugler KC, Doern GV (1997). In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother., 41(7): 1594-1597.
- Cai SF, Zhe Y, Xiao YH, Li CZ (2003). A double-blind randomized controlled trial of moxifloxacin in treatment of urinary tract infection. Chin. J. New Drugs. Clin. Rem., 22(8): 461-464.
- Cheadle W, Lee JT, Napolitano LM, Nichols RL (2010). Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections, Surg Infect (Larchmt). 11(5): 487-494.
- Foxman B (2002). Epidemiology of urinary tract infections: incidence, morbidity, and economic costs, Am. J. Med.,113 (1A): 5S-13S.
- Gao HY, Zeng HB, Lv YM (2005). Efficacy and safety of moxifloxacin in treatment of urinary tract infection, Clin. Intern. Med., 22(1): 37-39.
- Haggerty CL, Ness RB (2007). Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials, Clin. Infect., Dis., 44(7): 953-960.
- Hannan M, Cormican M, Flynn J (1993). A comparison of antimicrobial sensitivities of urinary pathogens for the years 1980 and 1990. Ir. J. Med. Sci., 162(12): 499-501.
- Heystek M, Ross JD (2009). A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease, Int. J. Std. Aids., 20(10): 690-695.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary, Control. Clin. Trials,17(1): 1-12.
- Jin X, Shou ZH (2009). Cost-effectiveness of moxifloxacin and sparfloxacin in treatment of urinary tract infection, Strait. Pharceutical., 21: 104-106.

- Judlin P, Liao Q, liu Z, Reimnitz P, Hampel B, Arvis P (2010). Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG, 117(12): 1475-1484.
- Juni P, Altman DG, Egger M (2001). Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ, 323: 42-46.
- Juni P, Egger M (2009). PRISMAtic reporting of systematic reviews and meta-analyses, Lancet, 374(9697): 1221-1223.
- Keating GM, Scott LJ (2004). Moxifloxacin: a review of its use in the management of bacterial infections, Drugs, 64(20): 2347-2377.
- Lau J, Ioannidis JP, Schmid CH (1998). Summing up evidence: one answer is not always enough, Lancet, 351(9096): 123-127.
- Lode HM, Schmidt LM (2008). Moxifloxacin: update and perspectives after 8 years of usage, Expert. Rev. Respir. Med., 2(4): 443-453.
- Li SQ (2008). Cost-effectiveness analysis of moxifloxacin and levofloxacin for treatment of urinary tract infection, Clin. Med., 28(2): 42-43.
- Luo JL, Xia XH, Huang SD (2006). Efficacy and Safety of Moxifloxacin for Treatment of Mycoplasma Infection in Urinary and Reproductive System, China. Pharmaceuicals, 15(20): 53-54.
- Luo XM, Li JX (2006). 56 cases analysis efficacy of Avelox in treatment of the urogenital mycoplasma chlamydial infection, Acta. Acad. Med. Weifang, 28: 474-475.
- Meng W, Ding Y (2009). Study on the efficacy of moxifloxacin hydrochloride tablets in treatment of acute pelvic inflammatory disease, J. Xinjiang. Med. Univer., 32(9): 1316-1318.
- Minichiello V, Hawkes G, Pitts M (2011). HIV, Sexually Transmitted Infections, and Sexuality in Later Life, Curr. Infect. Dis. Rep., 13(2): 182-187.
- Miravitlles M (2005). Moxifloxacin in respiratory tract infections, Expert. Opin. Pharmacother, 6(2): 283-293.
- Muijsers RB, Jarvis B (2002). Moxifloxacin in uncomplicated skin and skin structure infections, Drugs, 62(6): 967-975.
- Naber KG (2001). Which fluoroquinolones are suitable for the treatment of urinary tract infections, Int. J. Antimicrob. Agents, 17(4): 331-341.
- Omigie O, Okoror L, Umolu P, Ikuuh G (2009). Increasing resistance to quinolones: A four-year prospective study of urinary tract infection pathogens, Int. J. Gen. Med., 2: 171-175.
- Pathania R, Sharma SK (2010). Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves, Res. Vet. Sci., 89(1): 108-112.
- Pei YH, Wang G (2008). The efficacy of moxifloxaxin in treatment of female genital chlamydia mycoplasma infection, Chinese J. Misdiagnosis, 8(22): 5357-5358.
- Ross Cronje HS, Paszkowski T, Rakoczi I, Vildaite D, Kureishi A, Alefelder M, Arvis P, Reimnitz P (2006). Moxifloxacin verus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease :
  - results of a multicentre , double blind, randomised trial, Sex Transm. Infect., 82: 446-451.
- Souza JP, Pileggi C, Cecatti JG (2007). Assessment of funnel plot asymmetry and publication bias in reproductive health meta-analyses: an analytic survey, Reprod Health, 4: 3.
- Stass H, Kubitza D, Schuhly U (2001). Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration, Clin. Pharmacokinet, 40 1: 1-9.
- Su XD, Yang P (2010). Efficacy of moxifloxacin for non gonococcal urethritis, Heilongjiang. Med. Pharm., 33(1): 104-105.
- Sun GQ (2007). The efficacy and safety of moxifloxacin in in treating nongonococcal urethritis/Cervicitis, Hainan Med. J., 18: 128-147.
- Tang JD, Qiu DH, Cai H, Zhou MJ, Fei X, Xu QH, Wang M (2009). 50 cases analysis efficacy of moxifloxacin hydrochloride injection for urinary tract infection, Chinese J. Integrated. Traditional and Western Nephrol., 10(4): 349-350.
- Thompson SG (1994). Why sources of heterogeneity in meta-analysis should be investigated, BMJ, 309(6965): 1351-1355.
- Tian YP, Liu L, Zhang ZY, Chi BR (2005). Efficacy and safety of moxifloxacin for the treatment of genitourinary tract infection with drug resisance mycoplasma. Shenzhen J. interated traditional chinese and western Med., 15(6): 328-331.
- Van BF, Tulkens PM (2009). Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes, Drug. Saf., 32: 359-378.
- Wagenlehner FM, Naber KG (2006). Current challenges in the treatment

of complicated urinary tract infections and prostatitis, Clin. Microbiol. Infect., 12 (3): 67-80.

- Wagenlehner FM, Naber KG (2006). Treatment of bacterial urinary tract infections, presence and future, Eur. Urol., 49(2): 235-244.
- Wang G, Pei YH (2009). Moxifloxacin, Azithromycin, Minocycline for Treatment of Women's Nongonococcal Genito-urethritis, China Modern Doctor, 47(3): 25-26.
- Wang G, Pei YH (2009). Clinical study of moxifloxacin and gatifloxacin for treating women's urinary tract infection, China Pharmaceuticals, 18(11): 56-57.
- Wang X, Zeng YB, Xu JH (2009). Clinical efficacy of moxifloxacin in treating nongonococcal urethritis/Cervicitis, Chinese J/ Gen. Pract., 7(1): 9-10.
- Zhang YH, Lu JZ (2009). The cost-effectiveness analysis of patients with urinary tract infection with moxifloxacin and gatifloxacin. Chin. J. Postgrad. Med., 32(18):17-19

- Zhang HG, Li YJ, Dong CH (2007). Safety and Pharmacoeconomics of Moxifloxacin in the Management of Urinogenital Infection. Evaluation and Analysis of Drug-use in Hospitals of China, 7(2): 143-145.
- Zhang WF, Xie SX, Yang JX, Li JL (2004). Moxifloxacin in treatment of Mycoplasma infection in urinary and reproductive system: randomized controlled study, Chin. J. Nosocomiol., 14(5): 567-569.
- Zheng HZ (2010). Efficacy and cost-effectiveness of moxifloxacin and levofloxacin for urinary tract infection, China Pharmaceuticals, 19(7): 62-63.